Abstract
542 Background: Regorafenib significantly improved overall survival (OS) versus placebo in patients (pts) with uHCC who progressed on prior sorafenib therapy in the phase 3 RESORCE trial. The multicenter, international REFINE trial was designed to evaluate the safety and effectiveness of regorafenib in uHCC in the real-world setting. Methods: This prospective, observational trial aims to recruit 1000 pts with uHCC for whom a decision to treat with regorafenib has been made by the treating physician prior to enrollment according to the local health authority approved label. The primary endpoint is the incidence of treatment-emergent adverse events (TEAEs) and dose modifications due to TEAEs (NCI-CTCAE v4.03). Secondary endpoints are OS, progression-free survival, time to progression, best overall tumor response, and duration of treatment. Tumor response and progression are assessed per investigator according to local standard. An interim analysis includes the first 500 pts observed for ≥4 months. We report baseline characteristics, starting dose, and treatment duration for the interim analysis. Results: Of 498 pts evaluable for analysis, median age was 67 years (range: 22–91) and 84% were male. 59% were from Asia. Proportions of pts with ECOG performance status 0–1/≥2 were 82%/5% (missing 13%); 67% and 11% of pts had Child–Pugh A and B liver function, respectively (missing/not evaluable 21%). 60% of pts had metastases and 33% had vascular invasion. HCC etiology included hepatitis B 37%, alcohol use 26%, hepatitis C 23%, and NASH 7%. Baseline alpha-fetoprotein levels were < 400/≥400 ng/mL in 44%/26% of pts (missing 31%). The initial regorafenib dose was 160 mg/day (d) in 58% of pts, 120 mg/d in 13%, and 80 mg/d in 28% (8 pts initiated at 40 mg/d). The mean (SD) initial daily dose was 131 mg/d (37). Median duration of treatment was 3.7 months (IQR: 1.9–8.5). Conclusions: In this interim analysis of the observational REFINE study, some differences were observed in the characteristics of pts treated with regorafenib from the phase 3 RESORCE trial, reflecting less stringent inclusion criteria in a real-world study. Efficacy and safety analyses are ongoing. Clinical trial information: NCT03289273.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
